Question 1

What is BioNTech?

Accepted Answer

BioNTech is a Company.

Question 2

How often does BioNTech appear in global news?

Accepted Answer

Tracked across 4 news events drawn from 41 articles.

Question 3

When was BioNTech first tracked by Ergen?

Accepted Answer

First tracked on Mar 16, 2026.

Question 4

When was BioNTech last mentioned in news?

Accepted Answer

Last active on May 28, 2026.

Question 5

What is BioNTech's current news sentiment?

Accepted Answer

Aggregate sentiment score: 31 on a -100 to +100 scale (negative = critical coverage, positive = favorable coverage).

Question 6

How prominent is BioNTech in global news coverage?

Accepted Answer

Attention score of 6, derived from article volume and coverage intensity across 4 events.

Question 7

What is the most recent event involving BioNTech?

Accepted Answer

Pfizer, BioNTech Halt COVID Vaccine Trial (Apr 01, 2026, 6 articles).

Question 8

Who is BioNTech most connected to?

Accepted Answer

Top relationships: United States — Food and Drug Administration, United States — Food and Drug Administration.

Question 9

How did the "Pfizer, BioNTech Halt COVID Vaccine Trial" event impact BioNTech?

Accepted Answer

BioNTech, in collaboration with Pfizer, halted a large U.S. trial for their updated COVID-19 vaccine due to low enrollment, potentially impacting future approvals and market share for the 50-64 age group.

Question 10

How did the "BioNTech Trastuzumab Pamirtecan Phase 2 Success" event impact BioNTech?

Accepted Answer

BioNTech announced positive Phase 2 clinical trial results for trastuzumab pamirtecan, a HER2-targeted antibody-drug conjugate, in patients with endometrial cancer. This positive development could lead to a biologics license application in 2026 and further clinical trials, potentially increasing its market value and product pipeline.

Question 11

How did the "Boehringer, BioNTech ES-SCLC Trial" event impact BioNTech?

Accepted Answer

BioNTech is collaborating with Boehringer Ingelheim to evaluate a novel immuno-oncology combination in ES-SCLC. BioNTech will supply pumitamig and retains full rights to its asset.

Question 12

How is this data collected?

Accepted Answer

Ergen aggregates thousands of global news sources and extracts structured events, entities, and relationships with sentiment and attention metrics. Pages are daily static snapshots from the platform's live database.